Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2017 1
2018 1
2019 2
2020 6
2021 6
2022 7
2023 10
2024 13
2025 14
2026 24

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean ho tin lun (24 results)?
Tumor-migrating peripheral Foxp3-high regulatory T cells drive poor prognosis in HCC.
Huang CH, Ku WT, Mahalingam J, Wu CH, Wu TH, Fang JH, Su CW, Lin PT, Peng CW, Yang CK, Teng W, Jeng WJ, Chen WT, Lin CC, Lin SM, Sheen IS, Lin YC, Lin CY. Huang CH, et al. Among authors: lin pt. Hepatology. 2026 Jun 1;83(6):1398-1415. doi: 10.1097/HEP.0000000000001428. Epub 2025 Jul 1. Hepatology. 2026. PMID: 40590861
Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab.
Shen YC, Liu TH, Nicholas A, Soyama A, Yuan CT, Chen TC, Eguchi S, Yoshizumi T, Itoh S, Nakamura N, Kosaka H, Kaibori M, Ishii T, Hatano E, Ogawa C, Naganuma A, Kakizaki S, Cheng CH, Lin PT, Su YY, Chuang CH, Lu LC, Wu CJ, Wang HW, Rau KM, Hsu CH, Lin SM, Huang YH, Hernandez S, Finn RS, Kudo M, Cheng AL. Shen YC, et al. Among authors: lin pt. J Clin Oncol. 2024 Dec;42(34):4060-4070. doi: 10.1200/JCO.24.00645. Epub 2024 Aug 28. J Clin Oncol. 2024. PMID: 39197119 Free PMC article.
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma.
Lombardi P, Ramon-Gil E, Raja RQ, Brunetti L, Manfredi GF, Zhou Z, Merces G, Cappuyns S, Maria Fulgenzi CA, D'Alessio A, Torkpour A, Celsa C, Stefanini B, Yang H, Crowley F, Marron TU, Saeed A, Pinter M, Scheiner B, Huang YH, Lee PC, Nishida N, Po-Ting Lin R, Dalbeni A, Vivaldi C, Masi G, Rohlen N, von Felden J, Kaseb A, Galle PR, Kudo M, Hsu WF, Rimassa L, Parisi A, Kelley RK, Toyoda H, Pirisi M, Jabar F, Rakaee M, Cabibbo G, Cammà C, Piscaglia F, Hwang S, Shin DJ, Li M, Dekervel J, Guerra N, Meyer T, Reeves HL, Bengsch B, Daniele G, Mann DA, Chon HJ, Leslie J, Pinato DJ. Lombardi P, et al. Among authors: po ting lin r. J Hepatol. 2026 Nov;85(5):899-911. doi: 10.1016/j.jhep.2026.05.018. Epub 2026 Jun 15. J Hepatol. 2026. PMID: 42297215 Free article.
Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study.
Ueno M, Su YY, Takai A, Huang YH, Morimura H, Nishijima N, Lin SM, Chang CW, Iwamoto S, Nagatomo S, Lai HC, Mitani T, Ikeda A, Uenoyama Y, Umeda M, Chen SC, Chuang CH, Lai SW, Lee TY, Nakano S, Dai CY, Goto T, Su TH, Hsu CS, Lo CC, Takeda H, Osaki Y, Hatano E, Lee PC, Lin PT, Wang HW, Hsu WF, Liu TH, Seno H. Ueno M, et al. Among authors: lin pt. Liver Cancer. 2026 Jun 1. doi: 10.1159/000552808. Online ahead of print. Liver Cancer. 2026. PMID: 42495656 Free PMC article.
Addition of Intra-Arterial Therapy to Immunotherapy Improves Outcomes in Unresectable Hepatocellular Carcinoma: Taiwan Multicenter Cohort Study.
Lee TY, Lee PC, Shen YC, Hsu WF, Lai SW, Chang CW, Su YY, Su TH, Lin PT, Dai CY, Hsu CS, Chen SC, Rau KM, Lee IC, Jhan SR, Liu TH, Lai HC, Wang TE, Lin SM, Liang PC, Tseng CH, Chang PY, Wu SC, Wang HW, Lee SW, Huang YH; TRG investigators. Lee TY, et al. Among authors: lin pt. Liver Cancer. 2026 May 5. doi: 10.1159/000552375. Online ahead of print. Liver Cancer. 2026. PMID: 42421887 Free PMC article.
Prognostic role of the Child-Turcotte-Pugh classification and ALBI grade in patients without cirrhosis and hepatocellular carcinoma.
Balcar L, Brunetti L, Pomej K, Kreuter A, Maria Fulgenzi CA, Adnan A, Meischl T, D'Alessio A, Manfredi G, Chon HJ, Nishida N, Lee PC, Ang C, Krall A, Ben Khaled N, Stefanini B, Pressiani T, Eid JR, Saeed A, Parisi A, Huang YH, Arvind A, Vivaldi C, Salani F, Masi G, Röhlen N, Vogel A, Schulze K, von Felden J, Silletta M, Trauner M, Rapposelli IG, Wege H, Piscaglia F, Galle PR, Stauber R, Kudo M, Singal AG, Ulahannan SV, Andanamala H, Casadei-Gardini A, Bolnykh I, Mouri S, Roux C, Kaseb A, Rimassa L, Kang B, Celsa C, Li M, Pirisi M, Cammà C, Cabibbo G, Alimenti E, Iavarone M, Lombardi P, Kelley RK, Fortuny M, Reig M, Dalbeni A, Toyoda H, Hsu WF, Lin CY, Lin PT, Scheiner B, Allaire M, Pinato DJ, Pinter M. Balcar L, et al. Among authors: lin pt. JHEP Rep. 2026 Sep 30:102053. doi: 10.1016/j.jhepr.2026.102053. Online ahead of print. JHEP Rep. 2026. PMID: 42815636 Free article.
76 results